Evaluation of Clinical Outcomes, Tolerability, and Costs of Avelumab Maintenance and Pembrolizumab Second-Line Therapy in Advanced Urothelial Cancer.

NCT07207928 · clinicaltrials.gov ↗
COMPLETED
Status
35
Enrollment
OTHER
Sponsor class

Conditions

Sponsor

Azienda Ospedaliera Universitaria Integrata Verona

Collaborators